KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Year: 2018
Type: review
Abstract: Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of patients present advanced disease at onset. However, in the last decade, multiple oncogenic driver alterations have been discovered and each of them represents a potential therapeutic target. Although KRAS mutations are the most frequently oncogene aberrations in lung adenocarcinoma patients, effective therapies targeting KRAS have yet to be developed. Moreover, the role of KRAS oncogene in NSCLC remains unclear and its predictive and prognostic impact remains controversial. The study of the underlying biology of KRAS in NSCLC patients could help to determine potential candidates to evaluate novel targeted agents and combinations that may allow a tailored treatment for these patients. The aim of this review is to update the current knowledge about KRAS-mutated lung adenocarcinoma, including a historical overview, the biology of the molecular pathways involved, the clinical relevance of KRAS mutations as a prognostic and predictive marker and the potential therapeutic approaches for a personalized treatment of KRAS-mutated NSCLC patients.
Source: Molecular Cancer
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,090
Awards: G2055059721, G2098047078, G2120833963, The role of miRNAs in KRAS-driven Non-Small Cell Lung Cancer, G4369603142, G5417870047, G5518805754, G7868512380, Estudio pronóstico y predictivo de células tumorales circulantes (CTC) en adenocarcinoma de pulmón. Valoración in vivo del papel de Id1 e Id3 en la capacidad metastásica de las CTC, G8612953358
OpenAlex ID: W2795913084
